Ustekinumab and IL-17 inhibitors are commonly used in psoriasis and have also been trialled for SLE.44 45 While the future for JAK and TYK2 inhibitors in SLE is currently unknown, this therapeutic strategy is of high interest,52 particularly for patients with comorbid psoriasis. Here, IL17A is linked to systemic lupus erythematosus.